Y-90 Radioembolization
- Y-90 radioembolization (also called transarterial radioembolization, or TARE) delivers millions of tiny radioactive beads through the hepatic artery, lodging them inside a liver tumor's blood supply to irradiate it from the inside.
- The bead is yttrium-90, a pure beta-emitter with a short range — it cooks the tumor over a few millimeters and a couple of weeks, then quietly goes inert.
- It is not primarily an embolic procedure. Unlike TACE, Y-90 barely clogs vessels; it relies on radiation, not ischemia — so a patent portal vein is helpful but not mandatory.
- The whole thing happens in two visits: a mapping angiogram first, then the treatment weeks later. Skipping the map is how you accidentally irradiate a lung or a stomach.
- The feared complication is the bead going where it shouldn't — lung, gut, or skin — so meticulous mapping and dosimetry are the entire safety story.
Imagine you could pack a tumor's own plumbing with thousands of microscopic glowing pebbles, each one a tiny radioactive grenade with a fuse measured in days. You can. It's called Y-90 radioembolization, and it is one of the more delightfully sci-fi things interventional radiology does to the liver.
Why the liver is the perfect target
The liver has a beautifully exploitable quirk: it gets blood from two sources. Normal liver tissue drinks mostly from the portal vein, while liver tumors — primary hepatocellular carcinoma and many metastases — are greedy little things that build their own supply off the hepatic artery.
So if you inject something into the hepatic artery, it flows preferentially toward the tumor and largely spares the healthy liver. The tumor essentially sets its own table and we deliver the radiation directly to it. That arterial-vs-portal trick is the foundation of nearly every transarterial liver therapy.
What's actually in the syringe
The radiation comes from yttrium-90, a pure beta-emitter. Betas are short-range — in tissue they travel only a few millimeters before they run out of steam — which is exactly what you want. The dose dumps into the tumor and falls off a cliff before it reaches anything important next door. Y-90 also has a short half-life (a little under three days), so within a couple of weeks it has decayed to background and the beads are just inert specks sitting in the tumor forever.
Those beads come in two flavors — glass and resin microspheres — each only a few times wider than a red blood cell (tens of microns across). They're small enough to ride the bloodstream into the tumor's tiniest arteries and wedge there.
The "embolization" in the name oversells it. These spheres are sparse enough that they don't meaningfully starve the tumor of blood — the killing is done by radiation, not by choking off flow. That's the headline difference from bland or chemo-embolization, where the clog is the point.
Visit one: the mapping angiogram
You never just show up and inject Y-90. First comes a planning run, and it does three jobs.
First, map the anatomy. The interventionalist runs an angiogram to chart exactly which vessels feed the tumor and to hunt for sneaky branches that could carry beads to places you'd regret — most notoriously arteries heading toward the stomach or duodenum. Those get coiled off pre-emptively.
Second, measure the leak. A test dose of Tc-99m macroaggregated albumin (MAA) — particles that behave like a stand-in for the Y-90 spheres — is injected, then imaged on a nuclear scan. Because the liver and lung share a circulation, some particles inevitably sneak through tumor shunts into the lungs. That fraction is the lung shunt fraction, and if it's high, a treatment dose of beta radiation to the lungs causes a nasty radiation pneumonitis. A big shunt can disqualify a patient or force a dose reduction.
A high lung shunt fraction is the classic mapping showstopper. The MAA scan exists specifically to catch it before the real beads go in — once Y-90 is in the lungs, there is no undo button.
Third, calculate the dose. Using the tumor volume and the shunt data, the team prescribes how much activity to order. This radiation-dosimetry step is where Y-90 differs from a purely mechanical embolization — it borrows heavily from nuclear medicine principles.
Visit two: the treatment
Weeks later, the patient returns and the IR team re-catheterizes the same target vessel — ideally as selectively as possible, so the beads land in the tumor's territory and as little normal liver as possible. The Y-90 spheres go in, lodge in the tumor microvasculature, and start their slow beta burn.
Many centers then image the patient to confirm the beads went where intended, using either the bremsstrahlung the betas produce or the tiny amount of positron emission Y-90 also gives off (visible on PET). It's a satisfying "yes, it's exactly where we aimed" picture.
Who shouldn't get it, and what goes wrong
Contraindications cluster around the same theme: don't deliver radiation where it can't be contained or where the liver can't take the hit.
| Concern | Why it matters |
|---|---|
| High lung shunt fraction | Beta dose to lung → radiation pneumonitis. |
| Uncorrectable flow to gut | Non-target beads → ulcers, GI bleeding, gastritis. |
| Poor liver function / small reserve | The treated liver may not tolerate the radiation injury. |
The most common aftermath is post-radioembolization syndrome — fatigue, low-grade discomfort, sometimes nausea — usually milder than the post-embolization syndrome seen after TACE, because there's far less tissue ischemia. The scary complications are the non-target ones: radiation injury to lung, stomach, duodenum, or skin, and radioembolization-induced liver disease if too much healthy liver got dosed.
Think of Y-90 as a precision airstrike, not a siege. TACE besieges the tumor by cutting its supply lines; Y-90 flies a payload straight to the target and detonates locally. The entire safety game is making sure the payload doesn't drift off course — which is why the boring mapping visit is the part that actually keeps people safe.
If you remember one thing: Y-90 works by radiation delivered through the bloodstream, and every step of the workup exists to make sure that radiation lands on the tumor and nowhere else.